Expression
Restricted to epithelia; mainly in simple epithelium and basal membrane cells; strong overexpression in malignancies already at the stage of dysplasia (Litvinov et al., 1996) .
Localisation
Plasma membrane; baso-lateral in normal cells; redistribution on entire plasma membrane in vitro and in carcinoma cells.
Function
Homophilic cell-to-cell adhesion molecule (Litvinov et al., 1994) ; regulation of cadherin-mediated cell-to-cell adhesion (Litvinov et al., 1997) ; oncogenic signalling molecule, which is over-expressed in a plethora of carcinomas (Baeuerle and Gires, 2007) ; induces cell proliferation via induction of the proto-oncogene c-myc (Munz et al., 2004) ; intracellular domain of TACSTD1 /EpCAM is mandatory and sufficient for induction of cmyc gene expression; inhibition results in decreased proliferation and invasion (Osta et al., 2004) ; frequent use as a prognostic marker (Went et al., 2006; Spizzo et al., 2006) and therapeutic target (Baeuerle and Gires, 2007; RiethMüller et al., 1994; Schweizer et al., 2002; Amann et al., 2008; Ruf et al., 2007) .
Homology
Retroposon GA733-1; gp50/TROP-2 (Fornaro et al., 1995) , single-copy gene localised at chrom 1p32-31 TACSTD2, Accession CAA54801, 323 amino acids, calcium-dependent signalling protein. High homology of TACSTD1/EpCAM to TACSTD2/TROP-2/GA733-1), especially in the extracellular domain including cystein-rich EGF-like domains, conserved region similar to thyroglobulin type I repeat (Thyr I-like repeat).
Mutations
Note: So far, no mutations of the TACSTD1/epcam gene were described.
Implicated in

Colon cancer
Oncogenesis EpCAM is strongly overexpressed and was used as a molecular target for monoclonal, therapeutic antibody 17-1A (Panorex©) (RiethMüller et al., 1994) . EpCAM, in a complex with claudin-7, CD44 isoforms, and tetraspanins, is involved in colorectal cancer progression (Kuhn et al., 2007) .
Breast cancer
Prognosis
Increased expression of EpCAM is a marker for poor prognosis and overall survival of patients suffering from node-positive breast cancer (Spizzo et al., 2004) . Oncogenesis EpCAM is strongly overexpressed.
Ovarian cancer
Prognosis
Increased expression of EpCAM is a marker for poor prognosis and overall survival of patients suffering from ovarian cancer (Spizzo et al., 2006) . Oncogenesis EpCAM is strongly overexpressed.
Renal cancer (RCC)
Prognosis
Increased expression of EpCAM is a marker for improved prognosis in patients suffering from clear cell RCC and might help to discriminate between chromophobe RCC and oncocytomas (Went et al., 2005) . Oncogenesis EpCAM is strongly overexpressed in chromophobe RCC but not in oncocytomas.
Head and Neck Squamous Cell carcinomas (HNSCCs)
Prognosis Expression of EpCAM is a marker for disseminated tumour cells in HNSCCs (Chaubal et al., 1999) . Oncogenesis EpCAM is strongly overexpressed in HNSCCS.
Esophagus Squamous Cell carcinomas
Prognosis
Increased expression of EpCAM is a marker for decreased relapse-free survival (Stoecklein et al., 2006) . Oncogenesis EpCAM is strongly overexpressed.
Hepatocyte development
Note: EpCAM is strongly expressed in differentiation hepatocytes and progenitors thereof (Schmelzer et al., 2007; Schmelzer and Reid, 2008) .
Breakpoints
Note: No breakpoints described so far.
To be noted
Note: The gene name TACSTD1, for TumourAssociated Calcium Signalling Signal Transducer 1, is highly misleading and unappropriate. EpCAM, alias TACSTD1, is in fact a signal-transducing membrane protein (Munz et al., 2004) , however it is involved in calcium-independent homophilic cell-to-cell adhesion (Litvinov et al., 1994) . We shall therefore propose to use the term epcam for the gene and EpCAM for the protein (Baeuerle and Gires, 2007) . The characterisation of the molecular function of EpCAM in carcinoma cells pinpointed a role in signalling and regulation of gene transcription rather than cell-to-cell adhesion (Osta et al., 2004; Munz et al., 2004) . With respect to cell adhesion properties of EpCAM literature is even contradictory (Fornaro et al., 1995; Litvinov et al., 1994 ). More recent work described EpCAM as a marker for tumour-initiating cancer stem cells in a variety of entities including colon (Dalerba et al., 2007) , pancreas (Li et al., 2007) , and breast carcinomas (Al-Hajj et al., 2003) . A symposium on functions and clinical applications of EpCAM was initiated 2006 and will be held every two years. For more details please visit http://www.epcamsymposium.de .
